CRBU trades 309.8% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CRBU achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Caribou Biosciences, Inc. (CRBU) has a Wall Street consensus price target of $5.00, based on estimates from 9 covering analysts. With the stock currently trading at $1.22, this represents a potential upside of +309.8%. The company has a market capitalization of $121M.
Analyst price targets range from a low of $3.00 to a high of $7.00, representing a 80% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CRBU trades at a trailing P/E of -0.8x. Analysts expect EPS to grow +7.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EDITEditas Medicine, Inc. | $402M | $2.62 | $4.50 | +71.8% | Buy | — | 26 |
 BEAMBeam Therapeutics Inc. | $2.5B | $24.50 | $59.50 | +142.9% | Buy | — | 27 |
 NTLAIntellia Therapeutics, Inc. | $1.4B | $12.26 | $23.00 | +87.6% | Buy | — | 39 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.43 | $67.83 | +22.4% | Buy | — | 38 |
 FATEFate Therapeutics, Inc. | $270M | $2.32 | $5.63 | +142.7% | Buy | — | 31 |
 ALLOAllogene Therapeutics, Inc. | $518M | $1.50 | $6.43 | +328.7% | Buy | — | 30 |
 ILMNIllumina, Inc. | $41.3B | $273.04 | $237.00 | -13.2% | Buy | 51.0x | 50 |
 TMOThermo Fisher Scientific Inc. | $243.3B | $654.80 | $631.42 | -3.6% | Buy | 26.1x | 43 |
 PACBPacific Biosciences of California, Inc. | $789M | $2.54 | $1.18 | -53.5% | Buy | — | 18 |
 TWSTTwist Bioscience Corporation | $11.7B | $188.67 | $131.33 | -30.4% | Buy | — | 15 |
Quick answers to the most common questions about buying CRBU stock.
The consensus Wall Street price target for CRBU is $5, representing 309.8% upside from the current price of $1.22. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CRBU has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 309.8% upside from current levels.
CRBU's current price is $1.22 with a consensus target of $5 (309.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for CRBU, while the most conservative target is $3. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
CRBU is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CRBU stock forecast based on 9 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $3 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CRBU, with a "Buy" consensus rating and $5 price target (309.8% upside). 9 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CRBU analyst price targets range from $3 to $7, a 80% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.